Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
inobrodib + teclistamab
- Development stage
- Phase 2
- Lead developer
- CellCentric
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Subcutaneous
01
Overview
Inobrodib + teclistamab is a combination therapy being evaluated for the treatment of advanced hematological malignancies, primarily relapsed/refractory multiple myeloma. Inobrodib (CCS1477), developed by CellCentric, is a first-in-class, orally available small molecule inhibitor of the p300/CBP bromodomain. It selectively binds to the twin regulatory proteins p300 and CBP, which are transcriptional co-activators that drive the expression of key oncogenes such as MYC and IRF4. Teclistamab (Tecvayli) is a bispecific monoclonal antibody that acts as a T-cell engager, simultaneously targeting the B-cell maturation antigen (BCMA) on malignant plasma cells and the CD3 receptor on T cells to induce directed T-cell-mediated cytotoxicity. This combination is being investigated in Phase I/IIa clinical trials (such as NCT04068597) to explore whether the epigenetic modulation provided by inobrodib can enhance the efficacy or overcome resistance to BCMA-targeted immunotherapy in patients with heavily pretreated multiple myeloma.
- Other names
- CCS1477 + teclistamabinobrodib + teclistamab combination
02
Targets
BCMA (B-cell maturation antigen)CD3 (T-cell surface glycoprotein CD3)CREBBP BD (Creb-binding protein bromodomain)CREBBP (CREB-binding protein)EP300 (Histone acetyltransferase p300)
Beyond the preview
Go deeper on inobrodib + teclistamab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on inobrodib + teclistamab.